BioSpace News Archive

Concert Genetics has released a complete set of medical policies integrated with its catalog of more than 160,000 genetic testing products.

Luminopia today announced the publication of positive Phase 3 pivotal data of its investigational treatment for amblyopia—Luminopia One

PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner, Scancell, has selected its devices to administer its two SARS-CoV-2 DNA vaccine candidates, SCOV1 and SCOV2.

Waters Corporation (NYSE:WAT) today introduced the Waters™ BioAccord™ System with ACQUITY™ Premier, a combination of the Waters BioAccord System and the breakthrough ACQUITY Premier UPLC™ with MaxPeak™ High Performance Surface (HPS) technology.

Evogene Ltd. announced today that Mr. Ofer Haviv , Evogene’s President and CEO, will be interviewed in a “Fireside Chat” at the Cantor Virtual Global Healthcare Conference taking place on September 27-30, 2021.

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that it will be presenting at the Oppenheimer Fall Healthcare Summit being held virtually September 20-23, 2021.

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at this upcoming investor conference:

Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 blood test in optimizing individualized therapy for heart failure patients. Data were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM) 2021

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that the Company was awarded a $250,000 Phase I Small Business Innovation Research (SBIR) grant to develop and test the single-use sterile cell processing disposable, that will be used by the fully automated Quintessence System.

NLS Pharmaceutics Ltd. announces the initiation of its Phase 2 clinical trial evaluating Quilience® as a once-daily monotherapy for the treatment of excessive daytime sleepiness and cataplexy, the primary symptoms of narcolepsy.